Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization

L. J. Esserman, D. Sudilovsky, W. I. Kuo, Joe Gray, N. Hylton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Identifying characteristics of breast cancers that respond to neoadjuvant chemotherapy is a critical step toward tailoring therapies to maximize impact and minimize toxicity. Absence of estrogen receptor (ER) and presence of Her-2 has been shown to correlate with a good response to neoadjuvant therapy (nRx). We have identified several distinct MRI patterns in patients with locally advanced breast cancer (LABC) and sought to correlate known and new molecular markers with response to therapy. Methods: 46 patients with LABC had nRx with 4 cycles of Adriamycin (60 mg/m2) and Cytoxan (600 mg/m2). Serial breast MRI was used to estimate change in longest tumor diameter (LD). Tumors fell into 5 distinct categories and were characterized as types 1-5 (circumscribed mass, nodular pattern, diffuse pattern, patchy infiltration, septal spreading). Results: Residual disease at the time of surgical resection (a known predictor of outcome) correlated with post-therapy MRI LD with R2 of 0.94. Tumor grade correlated with MRI response. ER score (% positive cells x staining intensity) predicted response only in context of imaging type. Tumors of type 1 were highest grade, ER negative (72%), and had shrinkage sufficient for breast conservation (92%). Type 1 pattern strongly predicted response. Only 33%. demonstrated a partial or complete MR response (greater than one-third reduction in LD), but 87% of responders (13/15) had Type 1 tumors (p

Original languageEnglish (US)
Pages (from-to)245
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Comparative Genomic Hybridization
Estrogen Receptors
Magnetic Resonance Imaging
Breast Neoplasms
Neoplasms
Breast
Doxorubicin
Cyclophosphamide
Therapeutics
Staining and Labeling
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization. / Esserman, L. J.; Sudilovsky, D.; Kuo, W. I.; Gray, Joe; Hylton, N.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 245.

Research output: Contribution to journalArticle

@article{14616c9e13d748f19144b81685650a2f,
title = "Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization",
abstract = "Introduction: Identifying characteristics of breast cancers that respond to neoadjuvant chemotherapy is a critical step toward tailoring therapies to maximize impact and minimize toxicity. Absence of estrogen receptor (ER) and presence of Her-2 has been shown to correlate with a good response to neoadjuvant therapy (nRx). We have identified several distinct MRI patterns in patients with locally advanced breast cancer (LABC) and sought to correlate known and new molecular markers with response to therapy. Methods: 46 patients with LABC had nRx with 4 cycles of Adriamycin (60 mg/m2) and Cytoxan (600 mg/m2). Serial breast MRI was used to estimate change in longest tumor diameter (LD). Tumors fell into 5 distinct categories and were characterized as types 1-5 (circumscribed mass, nodular pattern, diffuse pattern, patchy infiltration, septal spreading). Results: Residual disease at the time of surgical resection (a known predictor of outcome) correlated with post-therapy MRI LD with R2 of 0.94. Tumor grade correlated with MRI response. ER score ({\%} positive cells x staining intensity) predicted response only in context of imaging type. Tumors of type 1 were highest grade, ER negative (72{\%}), and had shrinkage sufficient for breast conservation (92{\%}). Type 1 pattern strongly predicted response. Only 33{\%}. demonstrated a partial or complete MR response (greater than one-third reduction in LD), but 87{\%} of responders (13/15) had Type 1 tumors (p",
author = "Esserman, {L. J.} and D. Sudilovsky and Kuo, {W. I.} and Joe Gray and N. Hylton",
year = "2001",
language = "English (US)",
volume = "69",
pages = "245",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization

AU - Esserman, L. J.

AU - Sudilovsky, D.

AU - Kuo, W. I.

AU - Gray, Joe

AU - Hylton, N.

PY - 2001

Y1 - 2001

N2 - Introduction: Identifying characteristics of breast cancers that respond to neoadjuvant chemotherapy is a critical step toward tailoring therapies to maximize impact and minimize toxicity. Absence of estrogen receptor (ER) and presence of Her-2 has been shown to correlate with a good response to neoadjuvant therapy (nRx). We have identified several distinct MRI patterns in patients with locally advanced breast cancer (LABC) and sought to correlate known and new molecular markers with response to therapy. Methods: 46 patients with LABC had nRx with 4 cycles of Adriamycin (60 mg/m2) and Cytoxan (600 mg/m2). Serial breast MRI was used to estimate change in longest tumor diameter (LD). Tumors fell into 5 distinct categories and were characterized as types 1-5 (circumscribed mass, nodular pattern, diffuse pattern, patchy infiltration, septal spreading). Results: Residual disease at the time of surgical resection (a known predictor of outcome) correlated with post-therapy MRI LD with R2 of 0.94. Tumor grade correlated with MRI response. ER score (% positive cells x staining intensity) predicted response only in context of imaging type. Tumors of type 1 were highest grade, ER negative (72%), and had shrinkage sufficient for breast conservation (92%). Type 1 pattern strongly predicted response. Only 33%. demonstrated a partial or complete MR response (greater than one-third reduction in LD), but 87% of responders (13/15) had Type 1 tumors (p

AB - Introduction: Identifying characteristics of breast cancers that respond to neoadjuvant chemotherapy is a critical step toward tailoring therapies to maximize impact and minimize toxicity. Absence of estrogen receptor (ER) and presence of Her-2 has been shown to correlate with a good response to neoadjuvant therapy (nRx). We have identified several distinct MRI patterns in patients with locally advanced breast cancer (LABC) and sought to correlate known and new molecular markers with response to therapy. Methods: 46 patients with LABC had nRx with 4 cycles of Adriamycin (60 mg/m2) and Cytoxan (600 mg/m2). Serial breast MRI was used to estimate change in longest tumor diameter (LD). Tumors fell into 5 distinct categories and were characterized as types 1-5 (circumscribed mass, nodular pattern, diffuse pattern, patchy infiltration, septal spreading). Results: Residual disease at the time of surgical resection (a known predictor of outcome) correlated with post-therapy MRI LD with R2 of 0.94. Tumor grade correlated with MRI response. ER score (% positive cells x staining intensity) predicted response only in context of imaging type. Tumors of type 1 were highest grade, ER negative (72%), and had shrinkage sufficient for breast conservation (92%). Type 1 pattern strongly predicted response. Only 33%. demonstrated a partial or complete MR response (greater than one-third reduction in LD), but 87% of responders (13/15) had Type 1 tumors (p

UR - http://www.scopus.com/inward/record.url?scp=33749097446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749097446&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749097446

VL - 69

SP - 245

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -